This document was developed to provide practical guidance on interpretation of the most commonly used first- and second-line line probe assays (LPAs). In this updated manual, the interpretation of mutations identified by the assays has been revised to align with the WHO catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. The latest LPA instructions for use of the assays are also presented. Lastly, case studies are provided that support staff at national and regional TB reference laboratories to understand and manage any discrepancies between phenotypic and genotypic drug susceptibility testing results
2023
-
15 Jun 2023
-
14 Jun 2023
-
14 Jun 2023
-
8 Jun 2023
-
8 Jun 2023
-
25 Apr 2023
-
25 Apr 2023
-
25 Apr 2023
-
24 Apr 2023
-
24 Apr 2023
-
24 Apr 2023
-
24 Apr 2023
-
24 Apr 2023
-
24 Apr 2023
-
24 Apr 2023
-
20 Apr 2023
-
19 Apr 2023
-
19 Apr 2023
-
19 Apr 2023
-
19 Apr 2023
-
19 Apr 2023
-
12 Apr 2023
-
11 Apr 2023
-
11 Apr 2023
-
11 Apr 2023
-
11 Apr 2023
-
11 Apr 2023
-
11 Apr 2023
-
4 Apr 2023
-
3 Apr 2023
-
3 Apr 2023
-
3 Apr 2023
-
16 Mar 2023
-
16 Mar 2023
-
15 Mar 2023
-
14 Mar 2023
-
9 Mar 2023
-
9 Mar 2023
-
8 Mar 2023
-
8 Mar 2023
-
8 Mar 2023
-
8 Mar 2023
-
8 Mar 2023
-
13 Feb 2023
-
13 Feb 2023
-
13 Feb 2023
-
13 Feb 2023
-
7 Feb 2023
-
12 Jan 2023
-
12 Jan 2023
This manual provides practical guidance on the selection of molecular WHO-recommended rapid diagnostic (mWRD) and drug resistance tests for TB and drug-resistant TB. It is designed to be suitable for use in any country, with a customizable approach that assists users to tailor their selection efforts based on their local context. The document includes a stepwise approach to selection of one or more mWRDs and a decision pathway to follow. It also includes a description of all mWRDs recommended by WHO as of December 2021, as well as key considerations and questions to ask when making a final mWRD selection to best meet patient and program needs.